Revance: ePosters Showcase Data for DaxibotulinumtoxinA and RHA Line at Maui Derm

Three ePosters presented at the Maui Derm for Dermatologists 2021 meeting feature data for DaxibotulinumtoxinA for Injection and the RHA® Collection of hyaluronic acid based dermal fillers, both from Revance Therapeutics. 

Revance reported on the posters, which present findings from the open-label Phase 2 study evaluating DaxibotulinumtoxinA for Injection for the simultaneous treatment of moderate to severe upper facial lines (glabellar lines, forehead lines and lateral canthal lines), as well as data demonstrating the progressive effects of DaxibotulinumtoxinA for Injection on static/resting, glabellar lines with repeated treatment as a secondary analysis of data from the SAKURA Phase 3 program. Additionally, results of an in vitro study evaluating the ability of recombinant hyaluronidase to degrade the RHA® Collection of hyaluronic acid based dermal fillers, alongside a number of other commercially available HA fillers will be shared. 

Maui Derm for Dermatologists 2021 is being held in-person at the Grand Wailea in Maui, Hawaii from and broadcasted via live-stream for those unable to join in person. 

“At Maui Derm 2021, we are excited to present positive results from our Phase 2 upper facial lines study and data from the SAKURA Phase 3 program on static glabellar lines, in addition to the first in vitro data describing the sensitivity of the RHA® Collection to hyaluronidase degradation,” says Roman Rubio, Senior Vice President of Clinical Development at Revance.

ePoster abstracts are available online via the Maui Derm website at MauiDerm.com.